Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | RORA | P35398 | 1/20 | 0.34 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210116 | 1.00 | KMT2A (0.43) | KMT2AMEN1LMNAL3MBTL1POLB | |
| SCHEMBL2210803 | 0.95 | KMT2A (0.40) | KMT2AMEN1LMNAL3MBTL1POLB | |
| SCHEMBL2210807 | 0.95 | KMT2A (0.40) | KMT2AMEN1LMNAL3MBTL1POLB | |
| SCHEMBL2211161 | 0.89 | PPOX (0.36) | KMT2AMEN1LMNAL3MBTL1POLB | |
| SCHEMBL2211157 | 0.89 | PPOX (0.36) | KMT2AMEN1LMNAL3MBTL1POLB | |
| SCHEMBL2208355 | 0.88 | KMT2A (0.39) | KMT2AMEN1L3MBTL1POLBALDH1A1 | |
| SCHEMBL2208362 | 0.88 | KMT2A (0.39) | KMT2AMEN1L3MBTL1POLBALDH1A1 | |
| SCHEMBL2208363 | 0.84 | ALDH1A1 (0.34) | KMT2ALMNAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL2208359 | 0.84 | ALDH1A1 (0.34) | KMT2ALMNAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL2212119 | 0.84 | KDM4E (0.34) | KMT2AMEN1LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981827-B2 | Chiral phosphanes for use in asymmetric syntheses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20100099902-A1 | CHIRAL PHOSPHANES FOR USE IN ASYMMETRIC SYNTHESES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099902-A1 | CHIRAL PHOSPHANES FOR USE IN ASYMMETRIC SYNTHESES | PHOSPHO1, AGPS, GGPS1 | KMT2A 2926/4885MEN1 618/4885LMNA 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.